Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00771875 · ClinicalTrials.gov registry record · Phase 2
Randomized Trial for Mixed Acute Rejection
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00771875 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 30 participants.
The verdict
NCT00771875, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is being conducted to determine how safe and effective using an immune cell (b cell) depleting therapy and/or Thymoglobulin is in patients with a kidney transplant who are experiencing certain types of rejection.
Interventions
- DRUG Acetaminophen
- DRUG Rituximab
- DRUG Bortezomib
- DRUG Antihistamine
- DRUG Rabbit Antithymocyte Globulin (RATG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00771875
The ClinicalTrials.gov registry entry for NCT00771875 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Acetaminophen is the first listed.
NCT00771875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00771875 about?
NCT00771875 is a clinical study titled "Randomized Trial for Mixed Acute Rejection". This study is being conducted to determine how safe and effective using an immune cell (b cell) depleting therapy and/or Thymoglobulin is in patients with a kidney transplant who are experiencing certain types of rejection.
What is the current status of trial NCT00771875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2008-09. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00771875?
The interventions under investigation include: Acetaminophen (DRUG), Rituximab (DRUG), Bortezomib (DRUG), Antihistamine (DRUG), Rabbit Antithymocyte Globulin (RATG) (DRUG).
Who is sponsoring clinical trial NCT00771875?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.